Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMG 025

Next Previous
Drug Profile

IMG 025

Alternative Names: IMG-025

Latest Information Update: 01 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inmagene
  • Developer ImageneBio
  • Class Anti-infectives
  • Mechanism of Action MASP2 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - IgA nephropathy; Unspecified

Highest Development Phases

  • Preclinical IgA nephropathy; Infections

Most Recent Events

  • 28 Jul 2025 Ikena Oncology has merged with Inmagene to form ImageneBio
  • 15 Mar 2022 IMG 025 is available for licensing as of 15 Mar 2022. https://www.inmagenebio.com/outlicesing.html
  • 15 Mar 2022 Preclinical trials in IgA nephropathy in China (unspecified route), before March 2022 (Inmagene pipeline, March 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top